The Prevention Innovation Program III (PIP) encourages research applications in Non-vaccine Biomedical Prevention (nBP) research. The PIP is intended to support high-risk/innovative research and development efforts to establish and maintain a sustainable pipeline for the prevention of HIV acquisition/transmission.
The United States Agency for International Development (USAID) is seeking applications for a Cooperative Agreement from U.S. and non-U.S. non-profit Nongovernmental Organizations (NGOs), for profit NGOs, private voluntary organizations (PVOs), Institutions of Higher Education/Universities and Nongovernmental International Organizations -- excluding all prohibited source countries (i.e.
The purpose of this Funding Opportunity Announcement (FOA) is to promote multidisciplinary research programs that (1) devise optimal HIV prevention packages (combination interventions) for specific populations and (2) perform feasibility and acceptability studies to demonstrate that the proposed prevention package is acceptable to the target population and the study design is appropriate and feasible. This FOA is intended to encourage collaborations between behavioral and biomedical clinical specialists, epidemiologists, mathematical modelers, and clinical research specialists.
The purpose of this FOA is to support efforts to increase communication and dissemination of CDC-developed approaches to school-based programs for creating healthier adolescents (individuals in the 10-19 years age group) with reduced HIV infection and other STDs.
This Funding Opportunity Announcement (FOA) invites applications from institutions and organizations to participate in a cooperative research group, focusing on elucidating mechanisms regulating the development and function of the immune system in neonates (0-28 days) and infants (29 days – 12 months), including immune mechanisms triggered by non-pathogenic or pathogenic microbes (including HIV), vaccines, exposure to allergens, or alterations in immune function due to environmental exposures to pollutants.
This Funding Opportunity Announcement (FOA) encourages applications to support the optimization of monoclonal antibodies (mAb) or mAb derivatives that recognize and eliminate cells comprising the HIV reservoir.
This FOA will support one-year, services planning research grants to develop anepidemiologic understanding of opioid injection drug use, Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infection risk, and other adverse health consequences of such drug use, in conjunction with determining what resources/programs are currently available for addressing those problems, in any of the 420 Appalachian counties (www.arc.gov/counties).
In July 2015, through FOA CDC-RFA-PS15-1502, “Comprehensive High-Impact HIV Prevention Projects for Community-Based Organizations,” the Centers for Disease Control and Prevention (CDC) awarded funds to 90 CBOs to implement comprehensive HIV prevention programs to HIV-positive persons and high-risk HIV negative persons to reduce morbidity, mortality, and related health disparities.
This program will fund agencies that use a comprehensive, multidisciplinary approach to provide intervention and supervision services for youth with sexual behavior problems and treatment services for their child victims and families. Award recipients will target services for youth with sexual behavior problems, their child victim(s), and parents/caregivers of the offending youth and child victims. Youth participating in this program must undergo a mental health evaluation to determine if they are amenable to community-based treatment and intervention.